Further, although we demonstrated ICI in combination with chemotherapy might not improve survival outcomes over chemotherapy alone or plus angiogenesis inhibitors in NSCLC with EGFR ex20ins, corresponding results should be interpreted with caution due to the small sample size receiving immunotherapy in this study. This evidence concerns the gene EGFR and non-small cell lung carcinoma.